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intervention followed by 3 to 7 days of washout period.
Acupuncture in all groups was implemented at left LI10 with
manipulation after insertion, 5min, 10min after insertion fol-
lowed by needle removal. Microcirculation by laser Doppler
perfusion imaging (LDPI) was measured 5minutes before
acupuncture till 10minutes after removal of acupuncture. A
repeated measures ANOVA was used for statistical analysis.
Results: In each group, microperfusion increased by needle
insertion was maintained till after needle removal, and dif-
ferent needle size induced different blood perfusion changes,
with the increase in ST group signiﬁcantly higher than SP,
DT and DP groups (repeated measures ANOVA, P<0.0001), but
there was no signiﬁcant difference by needling depth.
Conclusion: ST intervention induced the greatest blood
perfusion changes comparedwith other interventions, but the
impact of different needling depths was not clear with blood
perfusion changes. Studies investigating other physiological
changes than blood perfusion by different acupuncture needle
sizes and needling depths are needed.
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Indirubin-3’-monoxime inhibits platelet
activation through suppression of
glycoprotein VI-mediated signal transduction
and a possible role for ERK
Jung-Jin Lee, Hyeeun Kwon, Jin Yeul Ma
Korea Institute of Oriental Medicine
Purpose: Indirubin-3’-monoxime (I3O), an active ingredi-
ent of Danggui Longhui Wan, exhibit antithrombotic activity
through antiplatelet activity. Hence, we investigated the
antiplatelet activity of I3O and the underlying mechanisms,
focusing on the possible involvement of phospholipase C2
(PLC2) and extracellular signal-regulated kinase (ERK) 1/2.
Methods: To identify the antithrombotic activity of I3O, we
investigated using FeCl3-induced thrombus formation model,
and platelet aggregation and coagulation ex vivo. In addition,
the mechanism by which I3O is mediated the antithrombotic
activity was assessed by determining platelet aggregation,
immunoblotting, adenylyl cyclase activity, arachidonic acid
(AA) liberation, and AA-metabolites conversion.
Results: In a rat carotid artery injury model, oral adminis-
tration (20mg/kg/day) of I3O for 3 days signiﬁcantly prolonged
occlusion time, andADP- and collagen-induced platelet aggre-
gation, comparable with aspirin. In washed platelets in vitro,
I3O potently inhibited collagen-induced platelet aggregation
by suppression of PLC2 phosphorylation, consistent with the
blockade of diacylglycerol (DAG) and AA formation, P-selectin
secretion and the production of thromboxane B2 (TXB2).
As expected, platelet aggregation induced by phorbol-12-
myristate 13-acetate (PMA), a protein kinase C (PKC) activator,
was inhibited by I3O. Both I3O and U0126 markedly reduced
collagen-induced phosphorylation of ERK1/2 and p47. Besides,
I3O generally suppressed phosphorylation of JNK, p38, GSK-
3, and AKT. Hence, we investigated to identify the effect of
I3O in collagen receptor level; as a result, I3O concentration-
dependently showed the inhibitionpattern in immunoﬂuores-
cence assay of glycoprotein VI (GPVI), as a collagen receptor.
Moreover, I3O not only inhibited the phosphorylation of the
tyrosine kinase Syk of GPVI but also suppressed the phos-
phorylation of PLC2 and ERK1/2 stimulated by convulxin, as
a speciﬁc stimulator.
Conclusion: Our results indicate that an antiplatelet effect
of I3O is due to the suppression of GPVI-mediated sig-
nal transduction. In collagen-stimulated platelet activation,
ERK1/2 phosphorylation is an adenylyl cyclase-dependent
pathway through modulation of PKC-p47 signaling and COX-
1-mediated AA metabolic pathways.
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Inhibitory effects of berberine on osteoclast
differentiation
SANG-YONG HAN, Ji-Hoon Kim,
Yun-Kyung Kim
Wonkwang University
Purpose: Osteoporosis is a bone desease that results from
imbalance between new bone formation and bone resorp-
tion leading to bone loss and is especially troublesome for
postmenopausal femaleswho suffer from estrogen deﬁciency.
Thus, the purpose of this study was to investigate new treat-
ment for osteoporosis.
Methods: We evaluate the effects of berberine on
receptor activator of nuclear factor-kB ligand (RANKL)-
induced osteoclast differentiation from bone marrow-derived
macrophages(BMMs) and performed cytotoxicity assay and
western blot analysis. The mRNA expression levels of the indi-
cated genes were analyzed by real-time PCR.
Results: We found that Berberine inhibits RANKL-induced
osteoclast differentiation in a dose-dependent manner with-
out affecting cytotoxicity. The mRNA expression of c-Fos,
nuclear factor of activated T cells cytoplasmic 1 (NFATc1),
tartrate-resistant acid phosphatase (TRAP), and osteoclast-
associated receptor (OSCAR) was considerably inhibited by
berberine treatment. berberine inhibited RANKL-mediated c-
Fos and NFATc1 expression in a dose- dependent manner.
Conclusion: In this study, we identiﬁed that berberine was
the efﬁcient inhibitor of RANKL-induced osteoclast differenti-
ation. Our results suggest that berberine may be useful in the
prevention of osteoporosis.
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